We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Should the FDA Approve Experimental Treatment for Severe Diseases?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Medical Ethics > Should the FDA Approve Experimental Treatment for Severe Diseases?
Medical EthicsMedical InnovationsNews

Should the FDA Approve Experimental Treatment for Severe Diseases?

Michael Kirsch
Michael Kirsch
Share
4 Min Read
SHARE
I’ve never had the pain and agony of having a kid who is truly sick.  Broken bones and minor surgeries don’t count.  Even one of my kid’s bout with malaria doesn’t rate, as this illness was easily cured.
 
Parents of kids with chronic illnesses would sacrifice anything to help their kids get better or to suffer less.  In the news recently is a conflict between families of kids with Duchenne muscular dystrophy and the Food and Drug Administration (FDA).  A very small study of an experimental
I’ve never had the pain and agony of having a kid who is truly sick.  Broken bones and minor surgeries don’t count.  Even one of my kid’s bout with malaria doesn’t rate, as this illness was easily cured.
 
Parents of kids with chronic illnesses would sacrifice anything to help their kids get better or to suffer less.  In the news recently is a conflict between families of kids with Duchenne muscular dystrophy and the Food and Drug Administration (FDA).  A very small study of an experimental drug called eteplirsen suggested some benefit.   Understandably, the families want the FDA to grant approval so that their kids and others could have access to this drug that will fight a dreadful disease that is fatal.  Families argue that these kids have nothing to lose and can’t wait another 5 years waiting for more definite evidence of efficacy to emerge. 
 
The FDA is legally required to approve drugs that are safe and effective. Obviously, the definitions of safe and effective are subjective, but the agency requires that a reasonable threshold be crossed for both of these parameters.  Gray areas create agonizing conundrums for agency officials and patient advocates. 
Should Unproven Treatements be Approved?
 
The FDA commissioned a committee, which will advise the agency proper, but did not advocate drug approval, which caused great consternation among family members and their supporters. These wrenching decisions must be guided by science and medical evidence, not hope and emotion.  Here are some potential objections to approving the medicine.
 
  • The study was too small to have persuasive scientific validity.
  • The study did not have a proper control group, which further weakened the conclusions.
  • The drug may have unknown and serious side-effects.  Once the drug is approved, physicians can prescribe it lawfully for a variety of diseases and illnesses, some of which may not be life-threatening.
  • Acceding to understandable family demands for premature FDA drug approval will prevent patients from entering larger clinical trials, preferably in a randomized study with a placebo control, where safety and efficacy can be more accurately verified.
  • If the FDA weakens its standards for approval for a single drug to respond to a constituency, then be prepared for mission creep to erode standards across the board over time.  
It’s the parents’ job to everything they can do to protect their kid.  It’s the FDA’s job to protect all of us.  I wish we could protect and save everyone.
TAGGED:clinical trialsFDA
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

If the Wife Takes an Antidepressant, is the Husband Protected From Suicide?

July 21, 2012
Target Marketing, Clinical Trial Marketing, Patient Recruitment
Business

Recruiting for Clinical Trials Using Business Marketing Techniques

March 15, 2014

WH Launches Front-End Program to Expand Healthcare Delivery Ahead of Reform

November 14, 2011
Global HealthcareHealth careNewsTechnology

Healthcare IT Conferences to Look Forward To in 2018

January 22, 2018
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?